Upadacitinib in Patients With Difficult-to-Treat Crohn’s Disease

Lay Summary Upadacitinib has recently been approved for treating Crohn’s disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with difficult-to-treat CD being cared for at clinical centers across Italy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Crohn's & colitis 360 2024-10, Vol.6 (4), p.otae060
Hauptverfasser:	Bezzio, Cristina, Franchellucci, Gianluca, Savarino, Edoardo V, Mastronardi, Mauro, Caprioli, Flavio Andrea, Bodini, Giorgia, Variola, Angela, Scaldaferri, Franco, Furfaro, Federica, Calabrese, Emma, Principi, Maria Beatrice, Biscaglia, Giuseppe, Marzo, Manuela, Michielan, Andrea, Cavalli, Carolina, Aratari, Annalisa, Campigotto, Michele, Ceccarelli, Linda, Cappello, Maria, Saibeni, Simone, Balestrieri, Paola, Soriano, Alessandra, Casini, Valentina, Bertani, Lorenzo, Barberio, Brigida, Conforti, Francesco Simone, Danese, Silvio, Armuzzi, Alessandro
Format:	Artikel
Sprache:	eng
Schlagworte:	Communications
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Lay Summary Upadacitinib has recently been approved for treating Crohn’s disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with difficult-to-treat CD being cared for at clinical centers across Italy.
ISSN:	2631-827X 2631-827X
DOI:	10.1093/crocol/otae060